Experimental Therapeutics Program

实验治疗学计划：综述 实验治疗(ET)计划的首要任务是发现和验证 治疗靶点，并随后识别、开发和测试新的治疗策略和生物标志物。 发现号科学家和临床医生之间的密切合作使我们能够对 从长凳到床边的迭代周期中的治疗策略。丰富的科学发现 人类发展研究中心的环境导致了一大批生物技术初创企业的发展，而 将发现转移到私营部门进行临床实施。大多数情况下，这采取的形式是 加州大学旧金山分校教职员工创办的早期生物技术初创企业。因此，该发现周期还可以包括`BASE到 因为从最初的发现到临床批准和采用的漫长弧线需要工业 参与的公司从早期的生物技术初创公司到制药公司。基因组和分子 成像靶点验证是ET计划的中心临床重点。前景看好的临床翻译 这些策略在HDfccc的早期临床试验单位进行了测试。除了帮助翻译 来自其成员的科学，ET计划充当整个HDfccc的临床翻译中心，因为 ET计划中的所有临床研究人员都参加疾病特定的现场委员会。这些调查人员 因此，作为工地委员会和 ET计划。ET方案的研究是在两个交叉主题下进行的： 主题1：肿瘤中的靶向信号转导 主题2：靶向表观遗传调控、细胞动态平衡和肿瘤环境 ET计划：关键指标 会员(13个系，2所学校)43 全额31 助理12 与癌症相关的资金(截至 21,511,484美元 2017/05/31) NCI$3,071,012 14% 同行评审3,740,309美元17% 非同行评审14,700,162美元68% 癌症相关出版物(2012/1-7/2017)672 方案间262 39% 方案内150 22% 高影响力189 28% 临床试验应计费用(2016)237 63 治疗性133 59 其他干预措施0 2 非干预性104 2

Experimental Therapeutics Program: Summary The overarching mission of the Experimental Therapeutics (ET) Program is to discover and validate therapeutic targets and subsequently identify, develop, and test novel therapeutic strategies and biomarkers. The close collaboration between discovery scientists and clinicians allows a multifaceted assessment of therapeutic strategies in iterative cycles from bench to bedside. Discoveries within the rich scientific environment of the HDFCCC have resulted in the development of a large number of biotech start-ups, and the movement of discoveries into the private sector for clinical implementation. Most often, this takes the form of early biotech start-ups launched by UCSF faculty. Thus, this discovery cycle can also include `bench to boardroom,' since the lengthy arc from initial discovery to clinical approval and adoption requires industrial participation ranging from early biotech start-ups to pharmaceutical companies. Genomic and molecular imaging target validation are a central clinical focus of the ET Program. Promising clinical translational strategies are tested in the HDFCCC Early Phase Clinical Trials Unit. In addition to facilitating translation of science from its members, the ET Program serves as a clinical translational hub for the entire HDFCCC, since all clinical investigators in the ET Program participate in disease-specific Site Committees. These investigators consequently serve as a two-way conduit of collaborative interactions between the Site Committees and the ET Program. Research in the ET Program is conducted under two cross-cutting themes: Theme 1: Targeting Signal Transduction in Cancer Theme 2: Targeting Epigenetic Modulation, Cellular Homeostasis, and the Tumor Environment ET Program: Key Metrics Membership (13 departments, 2 schools) 43 Full 31 Associate 12 Cancer-relevant Funding (direct costs as of $21,511,484 05/31/2017) NCI $3,071,012 14% Peer-reviewed $3,740,309 17% Non-peer-reviewed $14,700,162 68% Cancer-relevant Publications (1/2012-7/2017) 672 Inter-programmatic 262 39% Intra-Programmatic 150 22% High-Impact 189 28% Accruals to Clinical Trials (2016) 237 63 Therapeutic 133 59 Other Interventional 0 2 Non-interventional 104 2